沃特世2025财年营收增长7%，制药业务与创新产品驱动业绩

Core Insights - The company reported a total revenue of $3.165 billion for the fiscal year 2025, reflecting a year-over-year growth of 6.99% [1][2] - The fourth quarter revenue reached $932 million, also showing a year-over-year increase of 6.83% [1][2] - The overall gross margin for the year was 57.77%, with operating cash flow amounting to $653 million [1][2] Performance Overview - The pharmaceutical segment was a key growth driver, particularly in the Chinese market, with contract development and manufacturing organization (CDMO) and biotechnology customer areas achieving over 20% growth [3] - Significant growth was noted in the mass spectrometry and liquid chromatography product lines, with sales of the Alliance liquid chromatography system increasing by 270% and the Xevo TQ Absolute mass spectrometer (used for PFAS detection) growing by 40% [3] - The company invested approximately 10% of its product sales into research and development, with the bioprocessing business experiencing a 50% year-over-year growth [3] Strategic Developments - The acquisition of Becton Dickinson's biosciences and diagnostics business has been completed as planned, expected to yield significant synergies, including approximately $200 million in cost synergies over the next three years [4] - Management has established a clear growth framework for 2026, anticipating low single-digit growth from instrument replacement cycles, alongside contributions from GLP-1 testing, PFAS detection, and Indian genetic testing, totaling around 200 basis points [4] - The company aims for a compound annual growth rate of 7% over the next five years, exceeding the industry average of 4%, and plans to achieve approximately 450 basis points of margin expansion [4]